2.11 score from hupso.pl for:
one-ventures.com.au



HTML Content


Title oneventures - investment and venture capital

Length: 49, Words: 6
Description pusty

Length: 0, Words: 0
Keywords pusty
Robots index,follow
Charset UTF-8
Og Meta - Title pusty
Og Meta - Description pusty
Og Meta - Site name pusty
Tytuł powinien zawierać pomiędzy 10 a 70 znaków (ze spacjami), a mniej niż 12 słów w długości.
Meta opis powinien zawierać pomiędzy 50 a 160 znaków (łącznie ze spacjami), a mniej niż 24 słów w długości.
Kodowanie znaków powinny być określone , UTF-8 jest chyba najlepszy zestaw znaków, aby przejść z powodu UTF-8 jest bardziej międzynarodowy kodowaniem.
Otwarte obiekty wykresu powinny być obecne w stronie internetowej (więcej informacji na temat protokołu OpenGraph: http://ogp.me/)

SEO Content

Words/Characters 2318
Text/HTML 21.09 %
Headings H1 0
H2 13
H3 18
H4 4
H5 0
H6 0
H1
H2
about oneventures
the oneventures team
funds
investment portfolio
awards and accolades
latest news
data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test
data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test
clinical genomics strenghtens it's leadership team with multiple key appointments
media release - oneventures appoints dr graeme wald to life sciences investment team
dror ben-naim puts digital power in professor's hands
hr tech firm employment hero raises $3m to fund uk expansion
contact us
H3
connect with us
board of directors
innovation fund (fund i)
innovation and growth fund (fund ii)
information for stakeholders interested in the significant investment visa (siv) programme
oneventures innovation fund (fund i)
oneventures innovation and growth fund (fund ii)
other investments
smart sparrow
vaxxas
incoming media
incoming media
smart sparrow
vaxxas
for entrepreneurs
for investors
general enquiries
for media enquiries
H4 see all awards
see all news
sydney
brisbane
H5
H6
strong
dr michelle deaker
dr paul kelly
anne-marie birkill
graeme wald
daniel gammell
dr amir zalcenstein
james mcgrath
helen liu
jelly jakob
jen ball
walter lewin
simon moore
roger massy-greene
peter gammell
the oneventures innovation fund
the oneventures innovation and growth fund
application for funding
here
about clinical genomics
series a and beyond
information for stakeholders interested in the significant investment visa (siv) programme
b
i
em dr michelle deaker
dr paul kelly
anne-marie birkill
graeme wald
daniel gammell
dr amir zalcenstein
james mcgrath
helen liu
jelly jakob
jen ball
walter lewin
simon moore
roger massy-greene
peter gammell
the oneventures innovation fund
the oneventures innovation and growth fund
application for funding
here
about clinical genomics
series a and beyond
information for stakeholders interested in the significant investment visa (siv) programme
Bolds strong 21
b 0
i 0
em 21
Zawartość strony internetowej powinno zawierać więcej niż 250 słów, z stopa tekst / kod jest wyższy niż 20%.
Pozycji używać znaczników (h1, h2, h3, ...), aby określić temat sekcji lub ustępów na stronie, ale zwykle, użyj mniej niż 6 dla każdego tagu pozycje zachować swoją stronę zwięzły.
Styl używać silnych i kursywy znaczniki podkreślić swoje słowa kluczowe swojej stronie, ale nie nadużywać (mniej niż 16 silnych tagi i 16 znaczników kursywy)

Statystyki strony

twitter:title pusty
twitter:description pusty
google+ itemprop=name pusty
Pliki zewnętrzne 14
Pliki CSS 1
Pliki javascript 13
Plik należy zmniejszyć całkowite odwołanie plików (CSS + JavaScript) do 7-8 maksymalnie.

Linki wewnętrzne i zewnętrzne

Linki 94
Linki wewnętrzne 83
Linki zewnętrzne 11
Linki bez atrybutu Title 25
Linki z atrybutem NOFOLLOW 0
Linki - Użyj atrybutu tytuł dla każdego łącza. Nofollow link jest link, który nie pozwala wyszukiwarkom boty zrealizują są odnośniki no follow. Należy zwracać uwagę na ich użytkowania

Linki wewnętrzne

about us #aboutus
team #team
funds #funds
portfolio #portfolio
awards #awards
news #news
contact us #contactus
about us #aboutus
team #team
funds #funds
portfolio #portfolio
awards #awards
news #news
contact us #contactus
- /team/#mdeaker
- /team/#pkelly
- /team/#abirkill
- /team/#gwald
- /team/#dgammell
- /team/#azalcenstein
- /team/#jmcgrath
- /team/#hliu
- /team/#jjakob
- /team/
- /team/#wlewin
- /team/#smoore
- /team/#rmgreene
- /team/#pgammell
application for funding /contact-us/
here /contact-us/#contactus-siv
- /portfolio/#hatchtech
- /portfolio/#vaxxas
- /portfolio/#smartsparrow
- /portfolio/#palomamobile
- /portfolio/#buildingiq
- /portfolio/#incomingmedia
- /portfolio/#charmhealth
- /portfolio/#peak3
- /portfolio/#beasy
- /portfolio/#findme
- /portfolio/#clinicalgenomics
- /portfolio/#vaxxas-fundii
- /portfolio/#employmenthero
- /portfolio/#agamatrix
- /awards/
smart sparrow /portfolio/#smartsparrow
finalist in the bill and melinda gates foundation $20m digital courseware challenge /news-story/2014/10/02/smart-sparrow-wins-gates-e-learning-grant/
vaxxas /portfolio/#vaxxas
world economic forum technology pioneer 2015 /news-story/2014/08/28/vaxxas-selected-as-world-economic-forum-technology-pioneer-2015/
incoming media /portfolio/#incomingmedia
warner bros announces 2014 media camp class /news-story/2014/06/02/warner-bros.-entertainment-announces-2014-media-camp-class/
incoming media /portfolio/#incomingmedia
spiffy award nominee 2013 - ground breaking award for engineering /news-story/2013/07/24/2013-spiffy-award-nominees-announced---nominee-roster-catalogs-the-telecom-startup-watch-list/
smart sparrow /portfolio/#smartsparrow
vaxxas /portfolio/#vaxxas
see all awards /awards/
data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test news-story/2016/10/19/data-published-in-cancer-medicine-demostrate-clinical-genomics'-blood-test-for-colorectal-cancer-recurrence-is-two-fold-more-sensitive-than-cea-test
full story news-story/2016/10/19/data-published-in-cancer-medicine-demostrate-clinical-genomics'-blood-test-for-colorectal-cancer-recurrence-is-two-fold-more-sensitive-than-cea-test
data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test news-story/2016/10/19/data-published-in-cancer-medicine-demostrate-clinical-genomics'-blood-test-for-colorectal-cancer-recurrence-is-two-fold-more-sensitive-than-cea-test
full story news-story/2016/10/19/data-published-in-cancer-medicine-demostrate-clinical-genomics'-blood-test-for-colorectal-cancer-recurrence-is-two-fold-more-sensitive-than-cea-test
clinical genomics strenghtens it's leadership team with multiple key appointments news-story/2016/10/19/clinical-genomics-strenghtens-it's-leadership-team-with-multiple-key-appointments
full story news-story/2016/10/19/clinical-genomics-strenghtens-it's-leadership-team-with-multiple-key-appointments
media release - oneventures appoints dr graeme wald to life sciences investment team news-story/2016/09/01/media-release---oneventures-appoints-dr-graeme-wald-to-life-sciences-investment-team
full story news-story/2016/09/01/media-release---oneventures-appoints-dr-graeme-wald-to-life-sciences-investment-team
dror ben-naim puts digital power in professor's hands news-story/2016/07/22/dror-ben-naim-puts-digital-power-in-professor's-hands
full story news-story/2016/07/22/dror-ben-naim-puts-digital-power-in-professor's-hands
hr tech firm employment hero raises $3m to fund uk expansion news-story/2016/07/22/hr-tech-firm-employment-hero-raises-$3m-to-fund-uk-expansion
full story news-story/2016/07/22/hr-tech-firm-employment-hero-raises-$3m-to-fund-uk-expansion
see all news /news/
entrepreneurs@one-ventures.com mailto:entrepreneurs@one-ventures.com
back to the top #pagetop
disclaimer /disclaimer/
contact us /contact-us/

Linki zewnętrzne

- http://sb.co/programs/australia/
- http://headsoverheels.com.au/
- http://www.ilabaccelerator.com/
- https://investor.one-ventures.com/default.aspx
- http://linkedin.com/groups/oneventures-4458377?goback=.gan_4458377
global impact learning awards 2013 (silver) http://www.one-ventures.com.au/news-story/2013/07/18/smart-sparrow-wins-silver-at-learning-impact-2013-san-diego/
biospectrum emerging company of the year 2012 http://www.vaxxas.com/news/vaxxas-recognised-as-2013-biospectrum-asia-pacific-emerging-company-of-the-year/
cancer medicine http://onlinelibrary.wiley.com/doi/10.1002/cam4.868/abstract
www.clinicalgenomics.com http://www.clinicalgenomics.com/
austrade website http://www.austrade.gov.au/invest/significant-investor-visa-and-premium-investor-visa-programmes/
here http://www.avcal.com.au/avcalnews/new-significant-investor-visa-regulations-issued/

Zdjęcia

Zdjęcia 35
Zdjęcia bez atrybutu ALT 0
Zdjęcia bez atrybutu TITLE 7
Korzystanie Obraz ALT i TITLE atrybutu dla każdego obrazu.

Zdjęcia bez atrybutu TITLE

/images/default-source/oneventures_2.0/springboard_logo_120x56.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/heads-over-heels_logo_90x56.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/ilab_logo_80x56.jpg?sfvrsn=0
/images/portfolio-images/linkedin-monochrome.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/team_wlewin_201609_203x237.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/team_rmgreene_201609_203x237.jpg?sfvrsn=0
/images/default-source/oneventures_2.0/team_pgammell_201609_203x237.jpg?sfvrsn=0

Zdjęcia bez atrybutu ALT

empty

Ranking:


Alexa Traffic
Daily Global Rank Trend
Daily Reach (Percent)









Majestic SEO











Text on page:

about us team funds portfolio awards news contact us about us team funds portfolio awards news contact us oneventures is a venture capital firm headquartered in sydney, australia that provides human and investment capital into high growth companies with a particular focus on transformative technologies. the firm is particularly focused on opportunities originating in australia which are poised to expand into the established and emerging global markets. all of our partners have founded, built and exited high-growth businesses. our goal is to be the leading australian venture capital company. proudly supporting connect with us about oneventures oneventures invests in technology companies that serve or disrupt large high growth global markets. the firm has $170m in funds under management recently launching its new innovation and growth fund ii which is focused on growth and expansion stage technology companies. oneventures is managed by a team of partners with a skill-set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks. the oneventures team is committed to deliver investor returns by applying this expertise to select portfolio companies with significant potential then accelerating their performance. afsl oneventures management pty ltd is a designate under oneventures nominees pty ltd's afsl (licence no: 462825) issued by the australian securities and investments commissions, authorising the manager to provide such financial services as the manager provides during the course of its duties as manager of the fund. the oneventures team all partners have many years of c-level, board and investment experience. coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. the oneventures investment team has 7 technology related higher degrees. dr michelle deaker managing director and ceo dr paul kelly partner and managing director anne-marie birkill general partner and executive director graeme wald venture partner daniel gammell investment manager dr amir zalcenstein investment manager, healthcare james mcgrath investment analyst helen liu chief financial officer jelly jakob accounts jen ball office manager member name title board of directors walter lewin oneventures board of directors simon moore oneventures board of directors roger massy-greene oneventures board of directors peter gammell oneventures board of directors funds innovation fund (fund i) the oneventures innovation fund is a $40m venture capital fund formed as an early stage venture capital limited partnership. this fund was launched in 2010 with the commonwealth government committing $20m from its iif programme and this funding matched by high net-worth wholesale investors. innovation and growth fund (fund ii) the oneventures innovation and growth fund was launched in march 2014 with a target of $100m and reached that target in december 2015. fund ii is an early stage venture capital limited partnership backed entirely by australian high net-worth wholesale investors. focusing on later stage (series b and beyond) investments while still maintaining some investment activity in the earlier stage investments, fund ii is now screening investment opportunities where the experience of the oneventures management team can be leveraged to accelerate value creation and company success. we are currently looking for truly transformative companies to join our portfolio of innovative companies, if you think your company has what it takes, read our application for funding page and submit your application now. information for stakeholders interested in the significant investment visa (siv) programme information for stakeholders interested in the significant investment visa programme can be found here. investment portfolio oneventures innovation fund (fund i) oneventures innovation and growth fund (fund ii) other investments awards and accolades oneventures innovation fund (fund i) other investments smart sparrow september 30, 2014 finalist in the bill and melinda gates foundation $20m digital courseware challenge vaxxas august 26, 2014 world economic forum technology pioneer 2015 incoming media may 29, 2014 warner bros announces 2014 media camp class incoming media july 15, 2013 spiffy award nominee 2013 - ground breaking award for engineering smart sparrow may 2, 2013 global impact learning awards 2013 (silver) vaxxas march 18, 2013 biospectrum emerging company of the year 2012 see all awards latest news data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test by oneventures administrator | oct 19, 2016 12 october, 2016 media release clinical genomics presents data supporting novel 2-gene blood test for earlier detection of colorectal cancer recurrence at asco gi - results underscore clinical utility of novel circulating tumor dna assay to detect disease recurrence - bridgewater, n.j. – october 12, 2016 – clinical genomics, a private company developing innovative diagnostic tools for colorectal cancer, today announced that data supporting its two-gene circulating tumor dna (ctdna) blood test for post-surgical monitoring of colorectal cancer (crc) recurrence have been published online by cancer medicine, and will appear in the october issue. results demonstrate that the company's test detects twice the number of recurrence cases as carcinoembryonic antigen (cea) testing, a standard of care component for crc recurrence monitoring in patients who have undergone surgery. the test measures the presence of bcat1 and ikzf1 gene methylation, a chemical modification associated with tumor growth and invasion. preliminary data from this study were presented in january at the american society of clinical oncology 2016 gastrointestinal cancers symposium (asco gi). "given that at least 30 percent of patients in remission from crc following initial treatment will develop recurrence, improved surveillance methods that accurately detect recurrence are essential for improving outcomes for patients," said contributing study author dr. graeme p young, matthew flinders distinguished professor, flinders university centre for innovation in cancer, adelaide australia. "data from this study reinforce previous findings that ctdna can be reliably detected in crc patients. furthermore, the results suggest that when used in ongoing surveillance of cases in remission, a positive bcat1/ikzf1 test has the potential to establish a new approach for earlier detection of recurrent crc by detecting more unsuspected recurrences and triggering earlier imaging studies. additional prospective studies of the methylated bcat1/ikzf1 test compared with cea are ongoing." crc is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. when diagnosed early, before cancer has spread, the relative five-year survival rate for crc is 90 percent, but only approximately four out of 10 crc cases are detected early. among individuals undergoing surgical treatment for crc, recurrence occurs in 30 to 40 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment. this study compared the sensitivity and specificity of the two-gene blood test for methylated bcat1 and ikzf1 with those of cea in patients undergoing surveillance for recurrent crc following induction of remission. recurrence was assessed by clinical findings, blood testing and periodic computed tomographic surveillance scans. a total of 357 volunteers were recruited. recurrence status could be established for 220 subjects, of which 122 had blood samples available for analysis. of the 122 participants evaluated, 28 had recurrence and 94 had no clinically-detectable disease. among those with recurrent disease, 67.9 percent (19/28) were positive for methylated bcat1/ikzf1 (i.e. marker was detectable) while only 32.1 percent (9/28) were positive for cea (>5 ng/ml), representing a significant two-fold detection improvement with the two-gene test. among the 94 patients without clinically detectable recurrence there was no significant difference in the percentage positive for methylated bcat1/ikzf1 compared to cea. in this study population, sensitivity estimates of the methylated bcat1/ikzf1 test were 75 percent and 66.7 percent for local and distant recurrence, respectively, compared with 50 percent and 29.2 percent for cea. nine patients were positive for both tests, while the two-gene test detected an additional 10 cases that cea failed to detect in the blood sample collected closest to the time of radiologic assessment for recurrence. "an inability to detect early molecular changes consistent with underlying tumorigenesis can result in recurrent colorectal cancer going undetected or being discovered in the later stages of disease when clinical intervention is less likely to be effective," said lawrence lapointe, ph.d., president and ceo of clinical genomics. "these data demonstrate that a blood-based ctdna test for methylated bcat1/ikzf1 routinely detects recurrence that cea testing misses. we believe our two-gene test has the potential to fill an urgent and unmet clinical need, and are committed to advancing its clinical development as a new tool for improving patient outcomes." about clinical genomics clinical genomics is a privately held biotechnology company developing innovative products for colorectal cancer (crc) diagnosis. with a broad intellectual property portfolio consisting of more than 20 patents, clinical genomics, via its wholly-owned subsidiary enterix inc., currently offers the user-friendly, patient-preferred colorectal cancer screening insure® fit™ assay, a fecal immunochemical test that detects blood in the stool. insure is also marketed as a lab-based test in australia and other countries (colovantage home). building on an established history in the field of crc screening and diagnosis, clinical genomics developed a sensitive and specific blood-based circulating tumor dna (ctdna) test for colorectal cancer based on methylated dna from two genes, bcat1 and ikzf1. the company plans to offer this two-gene test for recurrence monitoring later in 2016. clinical genomics has offices and laboratories in bridgewater and edison, new jersey and sydney, australia, and operates as an fda-registered and tga-licensed manufacturer and a nata-accredited laboratory. for more information, please visit www.clinicalgenomics.com. full story data published in cancer medicine demostrate clinical genomics' blood test for colorectal cancer recurrence is two-fold more sensitive than cea test oct 19, 2016 full story clinical genomics strenghtens it's leadership team with multiple key appointments oct 19, 2016 full story media release - oneventures appoints dr graeme wald to life sciences investment team sep 01, 2016 full story dror ben-naim puts digital power in professor's hands jul 22, 2016 full story hr tech firm employment hero raises $3m to fund uk expansion jul 22, 2016 full story see all news contact us for entrepreneurs we are now screening companies for oneventures fund ii which is a series a and beyond growth fund focusing on the technology sector. to qualify for funding, your company should meet the following criteria: australian domiciled company we invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security if a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process if from another sector, your company should be generating sustainable revenue and have a strong market validation approaching profitability with capital required to fuel growth and global expansion if you meet the above criteria, send us a brief document (a 2-page executive summary or introductory powerpoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to entrepreneurs@one-ventures.com: summarize in 2 sentences what your company does (this is important) identify the market, value proposition and your competitive advantage tell us about your progress to date state your revenue for the last financial year and projected revenue for current financial year indicate capital required and how it will be used include 3 point bios of each executive and contact details we will review your proposal and endeavour to revert to you within 2 weeks. for investors investor enquiries: investors@one-ventures.com information for stakeholders interested in the significant investment visa (siv) programme the significant investor visa (siv) programme was revised with the announcement in may 2015 of a new complying investment framework. the new framework mandated that siv applicants would be required to invest a minimum of $500,000 at the at time of investment in an ausindustry registered fund(s): that is, a vclp, esvclp or an australian vc fund-of-fund as registered under the venture capital act 2002. the minimum amount is expected to be increased within two years as the market responds. the austrade website has more information regarding the programme available, including information sheets in english and chinese. the relevant regulations can be accessed here. oneventures is not at this time accepting new capital commitments and is therefore not in a position to receive funding from individual siv applicants. when this situation changes we will provide details here and on the avcal website. we are however receiving proposals from siv fund of funds interested in becoming a oneventures siv partner for 2016 and beyond. if you represent a fund of funds and meet the following criteria we request you submit a brief proposal for our consideration. our criteria: you should have a track record in servicing siv applicants you should have an established australian aml/ctf kyc compliance framework that oneventures can rely on in accepting siv funding you should be an ausindustry compliant fund of funds structure – oneventures will not accept direct investment from individual siv applicants at this stage you should have a fund of funds structure that can invest the capital for up to 10 years in line with our funding cycle your proposal should address those key criteria and provide information about: the directors the management team your track record in providing siv applicants with a return on investment how you will ensure aml/ctf kyc compliance including details of any external providers that support this process details of any relevant reporting and financial operational requirements we should consider your ability to source capital and the % of siv market you currently hold/expected quantum of capital you would be looking to deploy p.a. to vc we plan to work with up to 3 such partners only and will determine the parties with whom we wish to progress discussions by december 2015. general enquiries general enquiries: admin@one-ventures.com telephone: +61 2 8205 7379facsimile: +61 2 9247 9181 //--> sydney oneventures pty ltd suite 304, level 3 1 alfred street sydney nsw 2000 australia brisbane c/- interfinancial level 3, 145 eagle street brisbane qld 4000 australia for media enquiries back to the top for an interview with a oneventures' spokesperson, please contact honner media at +61 2 8248 3744. © 2015 oneventures pty ltd one vision, one team, one purpose disclaimer|contact us


Here you find all texts from your page as Google (googlebot) and others search engines seen it.

Words density analysis:

Numbers of all words: 2384

One word

Two words phrases

Three words phrases

the - 3.73% (89)
and - 3.23% (77)
for - 2.64% (63)
fund - 1.76% (42)
one - 1.68% (40)
venture - 1.64% (39)
can - 1.55% (37)
invest - 1.43% (34)
oneventures - 1.22% (29)
with - 1.22% (29)
test - 1.09% (26)
our - 1.09% (26)
you - 1.09% (26)
investment - 0.96% (23)
clinical - 0.88% (21)
recurrence - 0.8% (19)
are - 0.76% (18)
detect - 0.76% (18)
that - 0.76% (18)
any - 0.71% (17)
cancer - 0.67% (16)
this - 0.63% (15)
two - 0.59% (14)
gene - 0.59% (14)
late - 0.59% (14)
company - 0.55% (13)
australia - 0.55% (13)
siv - 0.55% (13)
your - 0.55% (13)
capital - 0.55% (13)
team - 0.5% (12)
growth - 0.5% (12)
genomics - 0.5% (12)
crc - 0.5% (12)
2016 - 0.46% (11)
blood - 0.46% (11)
from - 0.46% (11)
out - 0.46% (11)
new - 0.46% (11)
percent - 0.42% (10)
direct - 0.42% (10)
cea - 0.42% (10)
partner - 0.42% (10)
act - 0.42% (10)
tech - 0.42% (10)
all - 0.42% (10)
colorectal - 0.38% (9)
under - 0.38% (9)
should - 0.38% (9)
companies - 0.38% (9)
rate - 0.38% (9)
have - 0.38% (9)
stage - 0.38% (9)
ikzf1 - 0.38% (9)
innovation - 0.38% (9)
director - 0.38% (9)
bcat1 - 0.38% (9)
patient - 0.38% (9)
year - 0.38% (9)
funds - 0.34% (8)
more - 0.34% (8)
will - 0.34% (8)
current - 0.34% (8)
technology - 0.34% (8)
has - 0.34% (8)
market - 0.34% (8)
information - 0.34% (8)
data - 0.34% (8)
media - 0.34% (8)
dna - 0.34% (8)
award - 0.29% (7)
story - 0.29% (7)
full - 0.29% (7)
high - 0.29% (7)
patients - 0.29% (7)
significant - 0.29% (7)
following - 0.29% (7)
methylated - 0.29% (7)
investor - 0.29% (7)
oct - 0.25% (6)
directors - 0.25% (6)
programme - 0.25% (6)
was - 0.25% (6)
funding - 0.25% (6)
about - 0.25% (6)
two-gene - 0.25% (6)
were - 0.25% (6)
here - 0.25% (6)
partners - 0.25% (6)
australian - 0.25% (6)
its - 0.25% (6)
bcat1/ikzf1 - 0.25% (6)
contact - 0.25% (6)
work - 0.25% (6)
manager - 0.25% (6)
provide - 0.25% (6)
financial - 0.25% (6)
portfolio - 0.25% (6)
board - 0.25% (6)
point - 0.25% (6)
2013 - 0.21% (5)
criteria - 0.21% (5)
interested - 0.21% (5)
2015 - 0.21% (5)
going - 0.21% (5)
applicants - 0.21% (5)
not - 0.21% (5)
cases - 0.21% (5)
present - 0.21% (5)
positive - 0.21% (5)
develop - 0.21% (5)
study - 0.21% (5)
who - 0.21% (5)
establish - 0.21% (5)
tumor - 0.21% (5)
early - 0.21% (5)
2014 - 0.21% (5)
management - 0.21% (5)
(fund - 0.21% (5)
investments - 0.21% (5)
awards - 0.21% (5)
which - 0.21% (5)
focus - 0.21% (5)
global - 0.21% (5)
disease - 0.17% (4)
executive - 0.17% (4)
when - 0.17% (4)
established - 0.17% (4)
strong - 0.17% (4)
used - 0.17% (4)
recurrent - 0.17% (4)
than - 0.17% (4)
compared - 0.17% (4)
based - 0.17% (4)
result - 0.17% (4)
record - 0.17% (4)
track - 0.17% (4)
minimum - 0.17% (4)
screening - 0.17% (4)
ctdna - 0.17% (4)
pty - 0.17% (4)
years - 0.17% (4)
sydney - 0.17% (4)
earlier - 0.17% (4)
enquiries - 0.17% (4)
ltd - 0.17% (4)
support - 0.17% (4)
news - 0.17% (4)
details - 0.17% (4)
firm - 0.17% (4)
visa - 0.17% (4)
surveillance - 0.17% (4)
found - 0.17% (4)
investors - 0.17% (4)
other - 0.17% (4)
proposal - 0.17% (4)
detected - 0.17% (4)
remission - 0.13% (3)
experience - 0.13% (3)
treatment - 0.13% (3)
potential - 0.13% (3)
value - 0.13% (3)
each - 0.13% (3)
but - 0.13% (3)
only - 0.13% (3)
among - 0.13% (3)
supporting - 0.13% (3)
expansion - 0.13% (3)
opportunities - 0.13% (3)
level - 0.13% (3)
+61 - 0.13% (3)
ability - 0.13% (3)
accept - 0.13% (3)
individual - 0.13% (3)
registered - 0.13% (3)
particular - 0.13% (3)
framework - 0.13% (3)
how - 0.13% (3)
progress - 0.13% (3)
required - 0.13% (3)
revenue - 0.13% (3)
diagnosis - 0.13% (3)
meet - 0.13% (3)
beyond - 0.13% (3)
entrepreneurs - 0.13% (3)
jul - 0.13% (3)
please - 0.13% (3)
care - 0.13% (3)
tool - 0.13% (3)
time - 0.13% (3)
detectable - 0.13% (3)
had - 0.13% (3)
testing - 0.13% (3)
those - 0.13% (3)
markets - 0.13% (3)
business - 0.13% (3)
detects - 0.13% (3)
medicine - 0.13% (3)
graeme - 0.13% (3)
circulating - 0.13% (3)
results - 0.13% (3)
detection - 0.13% (3)
19, - 0.13% (3)
office - 0.13% (3)
sensitive - 0.13% (3)
two-fold - 0.13% (3)
published - 0.13% (3)
october - 0.13% (3)
may - 0.13% (3)
(siv) - 0.13% (3)
stakeholders - 0.13% (3)
later - 0.13% (3)
while - 0.13% (3)
innovative - 0.13% (3)
currently - 0.13% (3)
now - 0.13% (3)
– - 0.13% (3)
back - 0.13% (3)
monitoring - 0.13% (3)
general - 0.13% (3)
said - 0.08% (2)
within - 0.08% (2)
digital - 0.08% (2)
transformative - 0.08% (2)
bios - 0.08% (2)
sparrow - 0.08% (2)
smart - 0.08% (2)
enquiries: - 0.08% (2)
here. - 0.08% (2)
such - 0.08% (2)
partnership - 0.08% (2)
course - 0.08% (2)
would - 0.08% (2)
ausindustry - 0.08% (2)
particularly - 0.08% (2)
date - 0.08% (2)
is, - 0.08% (2)
send - 0.08% (2)
product - 0.08% (2)
chemical - 0.08% (2)
process - 0.08% (2)
december - 0.08% (2)
incoming - 0.08% (2)
2015. - 0.08% (2)
brief - 0.08% (2)
vaxxas - 0.08% (2)
document - 0.08% (2)
focused - 0.08% (2)
world - 0.08% (2)
points - 0.08% (2)
identify - 0.08% (2)
tell - 0.08% (2)
focusing - 0.08% (2)
into - 0.08% (2)
target - 0.08% (2)
line - 0.08% (2)
brisbane - 0.08% (2)
street - 0.08% (2)
demonstrate - 0.08% (2)
suite - 0.08% (2)
related - 0.08% (2)
looking - 0.08% (2)
ceo - 0.08% (2)
(crc) - 0.08% (2)
plan - 0.08% (2)
many - 0.08% (2)
consider - 0.08% (2)
what - 0.08% (2)
read - 0.08% (2)
return - 0.08% (2)
application - 0.08% (2)
expected - 0.08% (2)
provides - 0.08% (2)
website - 0.08% (2)
including - 0.08% (2)
relevant - 0.08% (2)
accepting - 0.08% (2)
position - 0.08% (2)
submit - 0.08% (2)
represent - 0.08% (2)
page - 0.08% (2)
sydney, - 0.08% (2)
aml/ctf - 0.08% (2)
kyc - 0.08% (2)
compliance - 0.08% (2)
rely - 0.08% (2)
structure - 0.08% (2)
security - 0.08% (2)
nominee - 0.08% (2)
criteria: - 0.08% (2)
developing - 0.08% (2)
$20m - 0.08% (2)
launched - 0.08% (2)
sensitivity - 0.08% (2)
limited - 0.08% (2)
cancer, - 0.08% (2)
surgical - 0.08% (2)
undergoing - 0.08% (2)
afsl - 0.08% (2)
initial - 0.08% (2)
healthcare - 0.08% (2)
release - 0.08% (2)
gammell - 0.08% (2)
novel - 0.08% (2)
deaths - 0.08% (2)
asco - 0.08% (2)
net-worth - 0.08% (2)
ongoing - 0.08% (2)
flinders - 0.08% (2)
findings - 0.08% (2)
outcomes - 0.08% (2)
improving - 0.08% (2)
assay - 0.08% (2)
genomics, - 0.08% (2)
committed - 0.08% (2)
private - 0.08% (2)
networks. - 0.08% (2)
wald - 0.08% (2)
approach - 0.08% (2)
recurrence, - 0.08% (2)
additional - 0.08% (2)
studies - 0.08% (2)
122 - 0.08% (2)
available - 0.08% (2)
author - 0.08% (2)
ii) - 0.08% (2)
emerging - 0.08% (2)
ground - 0.08% (2)
series - 0.08% (2)
learning - 0.08% (2)
march - 0.08% (2)
22, - 0.08% (2)
see - 0.08% (2)
power - 0.08% (2)
sep - 0.08% (2)
sciences - 0.08% (2)
managing - 0.08% (2)
key - 0.08% (2)
markets. - 0.08% (2)
leading - 0.08% (2)
bridgewater - 0.08% (2)
clinically - 0.08% (2)
demostrate - 0.08% (2)
genomics' - 0.08% (2)
there - 0.08% (2)
cea. - 0.08% (2)
sample - 0.08% (2)
wholesale - 0.08% (2)
changes - 0.08% (2)
large - 0.08% (2)
offer - 0.08% (2)
genomics. - 0.08% (2)
blood-based - 0.08% (2)
(ctdna) - 0.08% (2)
investors. - 0.08% (2)
insure - 0.08% (2)
specific - 0.08% (2)
life - 0.08% (2)
in the - 0.5% (12)
clinical genomics - 0.46% (11)
colorectal cancer - 0.38% (9)
of the - 0.34% (8)
test for - 0.34% (8)
with a - 0.29% (7)
full story - 0.25% (6)
blood test - 0.25% (6)
the oneventures - 0.25% (6)
fund ii - 0.25% (6)
methylated bcat1 - 0.25% (6)
venture capital - 0.25% (6)
2016 full - 0.21% (5)
fund (fund - 0.21% (5)
of directors - 0.21% (5)
growth fund - 0.21% (5)
oneventures innovation - 0.21% (5)
methylated bcat1/ikzf1 - 0.21% (5)
have a - 0.21% (5)
siv applicants - 0.21% (5)
for colorectal - 0.21% (5)
interested in - 0.21% (5)
this study - 0.17% (4)
growth and - 0.17% (4)
innovation fund - 0.17% (4)
the significant - 0.17% (4)
oneventures board - 0.17% (4)
positive for - 0.17% (4)
and growth - 0.17% (4)
pty ltd - 0.17% (4)
for methylated - 0.17% (4)
and be - 0.17% (4)
should have - 0.17% (4)
of funds - 0.17% (4)
track record - 0.17% (4)
you should - 0.17% (4)
fund of - 0.17% (4)
contact us - 0.17% (4)
your company - 0.17% (4)
innovation and - 0.17% (4)
two-gene test - 0.17% (4)
we are - 0.17% (4)
cancer recurrence - 0.13% (3)
to the - 0.13% (3)
the two-gene - 0.13% (3)
investment visa - 0.13% (3)
(fund i) - 0.13% (3)
in cancer - 0.13% (3)
cancer medicine - 0.13% (3)
cea test - 0.13% (3)
oct 19, - 0.13% (3)
19, 2016 - 0.13% (3)
meet the - 0.13% (3)
at this - 0.13% (3)
tumor dna - 0.13% (3)
circulating tumor - 0.13% (3)
for stakeholders - 0.13% (3)
and beyond - 0.13% (3)
technology companies - 0.13% (3)
at the - 0.13% (3)
bcat1/ikzf1 test - 0.13% (3)
for crc - 0.13% (3)
were positive - 0.13% (3)
and ikzf1 - 0.13% (3)
visa (siv) - 0.13% (3)
global markets - 0.13% (3)
oneventures is - 0.13% (3)
us about - 0.13% (3)
news contact - 0.13% (3)
with the - 0.13% (3)
significant investment - 0.13% (3)
if you - 0.13% (3)
information for - 0.13% (3)
stakeholders interested - 0.13% (3)
media release - 0.08% (2)
high growth - 0.08% (2)
life sciences - 0.08% (2)
global markets. - 0.08% (2)
the firm - 0.08% (2)
company should - 0.08% (2)
ii which - 0.08% (2)
now screening - 0.08% (2)
and networks. - 0.08% (2)
jul 22, - 0.08% (2)
companies with - 0.08% (2)
committed to - 0.08% (2)
the company - 0.08% (2)
the manager - 0.08% (2)
this is - 0.08% (2)
in technology - 0.08% (2)
two-fold more - 0.08% (2)
recurrence is - 0.08% (2)
genomics' blood - 0.08% (2)
demostrate clinical - 0.08% (2)
a track - 0.08% (2)
published in - 0.08% (2)
for recurrence - 0.08% (2)
sensitive than - 0.08% (2)
a brief - 0.08% (2)
partners have - 0.08% (2)
following criteria - 0.08% (2)
portfolio awards - 0.08% (2)
oneventures pty - 0.08% (2)
general enquiries - 0.08% (2)
details of - 0.08% (2)
of any - 0.08% (2)
kyc compliance - 0.08% (2)
a fund - 0.08% (2)
from individual - 0.08% (2)
aml/ctf kyc - 0.08% (2)
us team - 0.08% (2)
funds portfolio - 0.08% (2)
a oneventures - 0.08% (2)
should be - 0.08% (2)
awards news - 0.08% (2)
individual siv - 0.08% (2)
the market - 0.08% (2)
an ausindustry - 0.08% (2)
time of - 0.08% (2)
required to - 0.08% (2)
would be - 0.08% (2)
your proposal - 0.08% (2)
financial year - 0.08% (2)
sydney, australia - 0.08% (2)
in australia - 0.08% (2)
capital required - 0.08% (2)
networks. the - 0.08% (2)
test has - 0.08% (2)
cancer (crc) - 0.08% (2)
than cea - 0.08% (2)
fund was - 0.08% (2)
team funds - 0.08% (2)
dna (ctdna) - 0.08% (2)
launched in - 0.08% (2)
developing innovative - 0.08% (2)
december 2015. - 0.08% (2)
asco gi - 0.08% (2)
limited partnership - 0.08% (2)
detection of - 0.08% (2)
for earlier - 0.08% (2)
data supporting - 0.08% (2)
high net-worth - 0.08% (2)
more sensitive - 0.08% (2)
net-worth wholesale - 0.08% (2)
is two-fold - 0.08% (2)
wholesale investors. - 0.08% (2)
focusing on - 0.08% (2)
later stage - 0.08% (2)
clinical genomics' - 0.08% (2)
medicine demostrate - 0.08% (2)
oneventures management - 0.08% (2)
data published - 0.08% (2)
incoming media - 0.08% (2)
i) other - 0.08% (2)
our application - 0.08% (2)
for funding - 0.08% (2)
data from - 0.08% (2)
of clinical - 0.08% (2)
company developing - 0.08% (2)
early stage - 0.08% (2)
the potential - 0.08% (2)
demonstrate that - 0.08% (2)
that cea - 0.08% (2)
managing director - 0.08% (2)
percent and - 0.08% (2)
percent for - 0.08% (2)
and ceo - 0.08% (2)
partner and - 0.08% (2)
graeme wald - 0.08% (2)
investment manager - 0.08% (2)
in patients - 0.08% (2)
i) the - 0.08% (2)
following initial - 0.08% (2)
percent of - 0.08% (2)
of which - 0.08% (2)
this fund - 0.08% (2)
more than - 0.08% (2)
compared with - 0.08% (2)
the methylated - 0.08% (2)
recurrent crc - 0.08% (2)
potential to - 0.08% (2)
has the - 0.08% (2)
was launched - 0.08% (2)
used in - 0.08% (2)
for improving - 0.08% (2)
crc following - 0.08% (2)
about us - 0.08% (2)
2016 full story - 0.21% (5)
blood test for - 0.21% (5)
should have a - 0.17% (4)
and growth fund - 0.17% (4)
innovation and growth - 0.17% (4)
fund of funds - 0.17% (4)
were positive for - 0.13% (3)
interested in the - 0.13% (3)
significant investment visa - 0.13% (3)
fund (fund i) - 0.13% (3)
oneventures innovation fund - 0.13% (3)
visa (siv) programme - 0.13% (3)
oct 19, 2016 - 0.13% (3)
colorectal cancer recurrence - 0.13% (3)
circulating tumor dna - 0.13% (3)
bcat1 and ikzf1 - 0.13% (3)
test for colorectal - 0.13% (3)
for methylated bcat1/ikzf1 - 0.13% (3)
information for stakeholders - 0.13% (3)
the significant investment - 0.13% (3)
for stakeholders interested - 0.13% (3)
in the significant - 0.13% (3)
news contact us - 0.13% (3)
you should have - 0.13% (3)
innovation fund (fund - 0.13% (3)
stakeholders interested in - 0.13% (3)
from individual siv - 0.08% (2)
the potential to - 0.08% (2)
company developing innovative - 0.08% (2)
data published in - 0.08% (2)
of funds structure - 0.08% (2)
cancer medicine demostrate - 0.08% (2)
clinical genomics' blood - 0.08% (2)
aml/ctf kyc compliance - 0.08% (2)
cancer recurrence is - 0.08% (2)
two-fold more sensitive - 0.08% (2)
than cea test - 0.08% (2)
track record in - 0.08% (2)
investment visa (siv) - 0.08% (2)
22, 2016 full - 0.08% (2)
your company should - 0.08% (2)
fund ii which - 0.08% (2)
about us team - 0.08% (2)
tumor dna (ctdna) - 0.08% (2)
of the methylated - 0.08% (2)
early stage venture - 0.08% (2)
ii which is - 0.08% (2)
and networks. the - 0.08% (2)
networks. the oneventures - 0.08% (2)
i) the oneventures - 0.08% (2)
stage venture capital - 0.08% (2)
fund was launched - 0.08% (2)
net-worth wholesale investors. - 0.08% (2)
fund (fund ii) - 0.08% (2)
the oneventures innovation - 0.08% (2)
was launched in - 0.08% (2)
capital limited partnership - 0.08% (2)
earlier detection of - 0.08% (2)
oneventures innovation and - 0.08% (2)
growth fund (fund - 0.08% (2)
in cancer medicine - 0.08% (2)
demostrate clinical genomics' - 0.08% (2)
is two-fold more - 0.08% (2)
sensitive than cea - 0.08% (2)
funds portfolio awards - 0.08% (2)
colorectal cancer (crc) - 0.08% (2)
data from this - 0.08% (2)
from this study - 0.08% (2)
has the potential - 0.08% (2)
oneventures pty ltd - 0.08% (2)

Here you can find chart of all your popular one, two and three word phrases. Google and others search engines means your page is about words you use frequently.

Copyright © 2015-2016 hupso.pl. All rights reserved. FB | +G | Twitter

Hupso.pl jest serwisem internetowym, w którym jednym kliknieciem możesz szybko i łatwo sprawdź stronę www pod kątem SEO. Oferujemy darmowe pozycjonowanie stron internetowych oraz wycena domen i stron internetowych. Prowadzimy ranking polskich stron internetowych oraz ranking stron alexa.